C0220825||Evaluation
C0005507||VIDAS Anti-HCV Assay
C1511790||Detection
C4288963||Hepatitis C Virus Infection
C0166049||Anti-hepatitis C virus antibody
C0166049||Anti-hepatitis C virus antibody
C0005507||assays
C1710032||screening
C0027361||HCV -infected persons
C0005507||VIDAS Anti-HCV Assay
C0016674||France
C0022885||enzyme-linked fluorescence test
C0022771||Korea
C0005507||VIDAS assay
C1112419||HCV-positive
C1619717||HCV-negative
C0178913||blood samples
C0005507||Architect anti-HCV
C0041703||USA
C1709846||COBAS TaqMan HCV real-time PCR
C3828314||Roche Diagnostics
C0041703||USA
C0005507||Procleix Ultrio Plus Assay
C0041703||USA
C1290905||discrepant results
C2987205||recombinant immunoblot assay
C2987205||recombinant immunoblot assay
C1112419||HCV-positive
C1619717||HCV-negative
C0178913||samples
C0005507||VIDAS assay
C1290905||discrepant
C0178913||samples
C1446409||positive
C0019166||Core 2+
C0021054||NS3-2 2+
C0178913||samples
C0205160||negative
C0021054||NS4 2+
C2987205||recombinant immunoblot assay
C0005507||Architect assays
C0005507||VIDAS anti-HCV assay
C0020980||automated immunoassay platform
C0022877||laboratories
C0005507||Architect anti-HCV
C1709846||COBAS PCR assays
C4288963||HCV infection
C0456984||Weakly test-positive (ambiguous)
C0178913||samples
C0166049||Anti-hepatitis C virus antibody
C2987205||recombinant immunoblot assay
C1272251||HCV RNA assay